Jon Yankey, MS

Principal Biostatistician
Curevo Vaccine, Veristat Inc.

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-597) Amezosvatein Demonstrates Non-Inferior Immunogenicity and Superior Tolerability Head-to-Head vs Shingrix in a Phase 2 Herpes Zoster Vaccine Trial
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT